产品
编 号：F234844
分子式：C20H18N4O
分子量：330.38
分子式：C20H18N4O
分子量：330.38
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 187724-61-4
产品详情
生物活性：
PKI-166 is a potent, selective and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 0.7 nM.
体内研究：
PKI-166 (100 mg/kg; p.o.; daily; day 7-day 35 after xenograft) inhibits of pancreatic cancer growth.Animal Model:Male athymic nude mice with L3.6pl cells xenograft (8–12 weeks)
Dosage:100 mg/kg
Administration:Oral administration; daily; from day 7 to day 35 after xenograft
Result:Significantly decreased median tumor volume.
体外研究：
Pretreatment with PKI-166 (0-0.5 μM; 1 hour) inhibits EGFR autophosphorylation in human pancreatic cancer cells.PKI-166 (0.03μ M; 6 days) enhanced the cytotoxicity mediated by gemcitabine.
PKI-166 is a potent, selective and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 0.7 nM.
体内研究：
PKI-166 (100 mg/kg; p.o.; daily; day 7-day 35 after xenograft) inhibits of pancreatic cancer growth.Animal Model:Male athymic nude mice with L3.6pl cells xenograft (8–12 weeks)
Dosage:100 mg/kg
Administration:Oral administration; daily; from day 7 to day 35 after xenograft
Result:Significantly decreased median tumor volume.
体外研究：
Pretreatment with PKI-166 (0-0.5 μM; 1 hour) inhibits EGFR autophosphorylation in human pancreatic cancer cells.PKI-166 (0.03μ M; 6 days) enhanced the cytotoxicity mediated by gemcitabine.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备